Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine

https://doi.org/10.1016/0163-7258(90)90044-3Get rights and content

Abstract

People with genetic variants of cholinestrase respond abnormally to succinylcholine, experiencing substantial prolongation of muscle paralysis with apnea rather than the usual 2–6 min. The structure of usual cholinesterase has been determined including the complete amino acid and nucleotide sequence. This has allowed identification of altered amino acids and nucleotides. The variant most frequently found in patients who respond abnormally to succinylcholine is atypical cholonesterase, which occurs in homozygous from in 1 out of 3500 Caucasians. Atypical cholinesterase has a single substitution at nucleotide 209 which changes aspartic acid 70 to glycine. This suggests that Asp 70 is part of the anionic site, and that the absence of this negatively charged amino acid explains the reduced affinity of atypical cholinesterase for positively charged substrates and inhibitors. The clinical consequence of reduced affinity for succinylcholine is that one of the succinylcholine is hydrolyzed in blood and a large overdose reaches the nerve-muscle junction where junction where it causes prolonged muscle paralysis. Silent cholinesterase has a frame mutation at glycine 117 which prenaturely terminates protein synthesis and yields no enzyme. The K variant, named in honor of W. Kalow, has threonine in place of alanine 539. The K variant is associated with 33% lower activity. All variants arise from a single locus as there is only one gene for human cholinestrase (EC 3.1.1.8). Comparison of amino acid sequences of esterases and proteases shows that cholinesterase belongs to a new family of serine esterases which is different from the serine proteases.

References (119)

  • O. Lockridge et al.

    Comparison of atypical and usual human serum cholinesterase. Purification, number of active sites, substrate affinity, and turnover number

    J. biol. Chem.

    (1978)
  • O. Lockridge et al.

    Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase

    J. biol. Chem.

    (1982)
  • O. Lockridge et al.

    Interchain disulfide bonds and subunit organization in human serum cholinesterase

    J. biol. Chem.

    (1979)
  • O. Lockridge et al.

    Location of disulfide bonds within the sequence of human serum cholinesterase

    J. biol. Chem.

    (1987)
  • O. Lockridge et al.

    Complete amino acid sequence of human serum cholinesterase

    J. biol. Chem.

    (1987)
  • Z. Rakonczay

    Cholinesterase and its molecular forms in pathological states

    Prog. Neurobiol.

    (1988)
  • R.S. Rush et al.

    Aprophen: a substrate and inhibitor of butyrylcholinesterase and carboxylesterases

    Biochem. Pharmac.

    (1985)
  • D.H. Small

    Serum acetylcholinesterase possesses trypsin-like and carboxypeptidase B-like activity

    Neurosci. Lett.

    (1988)
  • D.H. Small et al.

    Acetylcholinesterase exhibits trypsin-like and metallopeptidase-like activity in cleaving a model peptide

    Neuroscience

    (1987)
  • K. Altland et al.

    Heterogeneity in the silent gene phenotype of pseudocholinesterase of human serum

    Biochem. Genet.

    (1970)
  • M. Arpagaus et al.

    Structure if the gene for human butyrylcholinesterase: evidence for a single copy

    Biochemistry

    (1990)
  • I. Azar et al.

    Response of a patient with atypical pseudocholinesterase to small intermittent succinyldicholine doses

    Anesthesiology

    (1981)
  • A. Baraka et al.

    Response of the newborn to succinylcholine injection in homozygotic atypical mothers

    Anesthesiology

    (1975)
  • C.F. Bartell et al.

    A polymorphism (K variant?) of human serumn cholinesterase at nucleotide 1615, coding for Ala/Thr 539

    FASEB J.

    (1989)
  • F. Bergman et al.

    The structure of the active surface of serum cholinesterase

    Biochim. biophys. Acta

    (1954)
  • R. Boopathy et al.

    Chemical modification of the bifunctional human serum pseudocholinesterase. Effect on the pseudocholinesterase and acyl arylamidase activities

    Eur. J. Biochem.

    (1985)
  • R. Boopathy et al.

    A peptidase activity exhibited by human serum pseudocholinesterase

    Eur. J. Bicohem.

    (1987)
  • S. Brimijoin et al.

    Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay

    J. Neurochem.

    (1988)
  • S. Brimijoin et al.

    Production and characterizaton of separate monoclonal antibodies to human acetylcholinesterase and butyrylcholinesterase

    Molec. Pharmac.

    (1983)
  • L.M. Chan et al.

    Active-site-directed fluorescent probes in the kinetics and spectroscopy of furified horse serum cholinesterase

    Biochemistry

    (1974)
  • S.W. Clark et al.

    Properties of plasma cholinesterase variants

    Ann. N.Y. Acad. Sci.

    (1968)
  • J.A. Cohen et al.

    The active site of esterases

    J. cell. comp. Physiol

    (1959)
  • P.J. Cohen et al.

    A simple test for abnormal psudocholinesterase

    Anesthesiology

    (1970)
  • P.K. Das et al.

    Purufucation and properties of human serum cholinesterase

    Biochem. J.

    (1970)
  • R.O. Davies et al.

    The action of normal and atypical cholinesterase of human seru, upon a series of esters of choline

    Can. J. Biochem. Physiol.

    (1960)
  • P. Devenyl

    Cocaine complications and psuedocholinesterase

    Ann. int. Med.

    (1989)
  • A. Doenicke et al.

    Serum cholinesterase anenzymia. Report of a case confirmed by enzyme-histological examination of liver-biopsy specimen

    Acta anaesth. scand.

    (1963)
  • J.R. Downs

    Atypical cholinesterase activity: its importance in dentistry

    J. oral Surg.

    (1966)
  • H.W. Eckerson et al.

    Immunological comparison of the usual and atypical human serum cholinesterase phenotypes

    Biochem. Genet.

    (1983)
  • H.W. Eckerson et al.

    The human serum paraoxonase/arylesterase polymorphism

    Am. J. hum. Genet.

    (1983)
  • R.T. Evans et al.

    On the identification anf frequency of the J and K cholinesterase phenotypes in a Caucasian population

    J. med. Genet.

    (1984)
  • D.M. Fischer et al.

    The influence of bumbuterol (carbamylated terbutaline) on the duration of action of succinylcholine-induced paralysis in humans

    Anesthesiology

    (1988)
  • F.F. Foldes et al.

    The intravenous toxicity of local anesthetic agents in man

    Clin. Pharmac. Ther.

    (1965)
  • P. Garry et al.

    New allele at cholinesterase locus 1

    J. med. Genet.

    (1976)
  • H.W. Goede et al.

    Hydrolysis of succinydicholine and succinylmonocholine in human serum

    Molec. Pharmac.

    (1968)
  • L.M.C. Hall et al.

    The Ace locus of Drosophila melanogaster: structural gene for acetylcholinesterase with an unusual 5′ leader

    EMBO J.

    (1986)
  • H. Harris

    The Principles of Human Biochemical Genetics

  • H. Harris et al.

    Differential inhibition of human serum cholinesterase with fluoride: recognition of two phenotypes

    Nature

    (1961)
  • H. Haupt et al.

    Isolierung und physikalisch-chemische Characterisierung der cholinesterase aus Humanserum

    But

    (1966)
  • L.B. Hersh et al.

    Kinetics of succinyldithiocholine hydrolysis by serum cholinterase: comparison to dibucaine and succinylcholine numbers

    J. Pharmac. exp. Ther.

    (1974)
  • Cited by (202)

    • Aerosolized recombinant human butyrylcholinesterase delivered by a nebulizer provides long term protection against inhaled paraoxon in macaques

      2019, Chemico-Biological Interactions
      Citation Excerpt :

      Usually, treatment of OP poisoning consists of supportive care and specific post exposure therapy e.g. atropine and oximes e.g. 2-PAM [5,6], which often fail to prevent morbidity or death because they do not efficiently pass the blood-brain-barrier [7]. To date, the stoichiometric tetrameric human plasma enzyme, butyrylcholinesterase (HuBChE)(EC3.1.1.8, pseudo-cholinesterase, nonspecific cholinesterase) [8], has been the leading pretreatment candidate against OP exposure [9–11]. Due to limited availability and cost, focus on an efficacious OP countermeasure has switched to the development of recombinant (r) HuBChE [12–16] or alternate catalytic bioscavengers [17–19].

    • Pseudocholinesterase Deficiency: What the Proceduralist Needs to Know

      2019, American Journal of the Medical Sciences
    View all citing articles on Scopus
    View full text